BANK VONTOBEL/CALL/ELI LILLY & CO/440/0.1/21.06.24 | Delayed Deutsche Boerse AG 07:45:32 2024-05-23 am EDT | ||
| 34.01 EUR | +1.49% |
|
| Current month | +4.75% | ||
| 1 month | +18.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 34.01 | +1.49% |
| 24-05-22 | 33.51 | -1.50% |
| 24-05-21 | 34.02 | +7.15% |
| 24-05-20 | 31.75 | +3.05% |
| 24-05-17 | 30.81 | -1.25% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 07:45 am EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6BRB |
| ISIN | DE000VU6BRB5 |
| Date issued | 2023-04-17 |
| Strike | 440 $ |
| Maturity | 2024-06-21 (29 Days) |
| Parity | 10 : 1 |
| Emission price | 2.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.3 € |
|---|---|
| Lowest since issue | 2.37 € |
| Spread | 0.13 € |
| Spread % | 0.38% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- Warrant
